Key Takeaways From C4 Therapeutics Analyst Ratings


C4 Therapeutics CCCC underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 0 2 0 0
Last 30D 1 0 1 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 1 0 1 0 0

In the assessment of 12-month price targets, analysts unveil insights for C4 Therapeutics, presenting an average target of $10.75, a high estimate of $14.00, and a low estimate of $8.00. This upward trend is evident, with the current average reflecting a 30.3% increase from the previous average price target of $8.25.

Diving into Analyst Ratings: An In-Depth Exploration

A clear picture of C4 Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Derek Archila Wells Fargo Raises Equal-Weight $8.00 $7.00
Bradley Canino Stifel Raises Buy $14.00 $13.00
Terence Flynn Morgan Stanley Raises Equal-Weight $8.00 $1.00
Bradley Canino Stifel Raises Buy $13.00 $12.00

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to C4 Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of C4 Therapeutics compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for C4 Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of C4 Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on C4 Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know C4 Therapeutics Better

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Understanding the Numbers: C4 Therapeutics's Finances

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: Over the 3 months period, C4 Therapeutics showcased positive performance, achieving a revenue growth rate of 14.26% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1065.75%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): C4 Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.04%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): C4 Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.8%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: C4 Therapeutics's debt-to-equity ratio is below the industry average at 0.29, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!